Champions Oncology (CSBR) Accumulated Expenses (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Accumulated Expenses of $2.6 million for Q2 2026, up 1.41% year-over-year from $2.6 million in Q2 2025, and down 22.53% quarter-over-quarter from $3.3 million in Q1 2026.
Champions Oncology (CSBR) Accumulated Expenses (2011 - 2026) Analysis & Trends
Champions Oncology's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $2.6 million for Q2 2026.
- In Q2 2026, Accumulated Expenses rose 1.41% year-over-year to $2.6 million; the TTM figure through Apr 2026 stood at $2.6 million (up 1.41% YoY), while the FY2026 annual figure was $2.6 million, up 1.41% from the prior year.
- Accumulated Expenses for Q2 2026 stood at $2.6 million, down from $3.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $3.3 million in Q1 2026, with the low at $1.7 million in Q4 2022.
- The 5-year median for Accumulated Expenses is $2.2 million (2024), against an average of $2.2 million.
- The sharpest annual moves came in 2025 and 2026: Accumulated Expenses decreased 14.12% in 2025, then surged 47.6% in 2026.
- Champions Oncology's Accumulated Expenses stood at $1.7 million in 2022, then rose by 21.14% to $2.0 million in 2023, then gained by 10.48% to $2.2 million in 2024, then decreased by 2.1% to $2.2 million in 2025, then gained by 18.46% to $2.6 million in 2026.
- Business Quant data shows CSBR's Accumulated Expenses at $2.6 million in Q2 2026, $3.3 million in Q1 2026, and $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.59 Mn |
| Jan 31, 2026 | 3.35 Mn |
| Oct 31, 2025 | 2.19 Mn |
| Jul 31, 2025 | 1.80 Mn |
| Apr 30, 2025 | 2.56 Mn |
| Jan 31, 2025 | 2.27 Mn |
| Oct 31, 2024 | 2.24 Mn |
| Jul 31, 2024 | 2.10 Mn |
| Apr 30, 2024 | 2.16 Mn |
| Jan 31, 2024 | 2.43 Mn |
| Oct 31, 2023 | 2.02 Mn |
| Jul 31, 2023 | 2.09 Mn |
| Apr 30, 2023 | 2.27 Mn |
| Jan 31, 2023 | 2.03 Mn |
| Oct 31, 2022 | 1.67 Mn |
| Jul 31, 2022 | 1.96 Mn |
| Apr 30, 2022 | 2.41 Mn |
| Jan 31, 2022 | 2.03 Mn |
| Oct 31, 2021 | 1.91 Mn |
| Jul 31, 2021 | 1.98 Mn |